ArticleHaematologica2015

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".

Sung-Hyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.